Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences    GILD

GILEAD SCIENCES

(GILD)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

New Gilead Sciences CFO Expected to Pursue More Deals to Expand Portfolio

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/15/2019 | 05:49pm EST

By Nina Trentmann

Biopharmaceutical giant Gilead Sciences Inc. selected an internal candidate to become its next finance chief, filling a key position on its leadership team as the company looks to further expand its portfolio beyond its core HIV treatments.

The Foster City, Calif.-based company Tuesday said it appointed Andrew Dickinson as chief financial officer, effective Nov. 1. Mr. Dickinson, currently executive vice president for corporate development and strategy, joined Gilead in 2016 following a nine-year tenure in investment banking. He will succeed Robin Washington, who is set to retire from the CFO role but will remain in an advisory capacity until early next year. Ms. Washington's planned retirement was announced in April.

Chief Executive Daniel O'Day -- who took the reins this year after a career at Roche Holding AG -- in recent months made several key appointments at Gilead, including a new chief medical officer and a new head of its commercial division. "With the new CEO, CMO and CFO now in place, this effectively marks the end of a transition period for the company," analysts at RBC Capital Markets LLC wrote in a note to clients.

Gilead described Mr. Dickinson as the architect behind the company's 2017 $11.9 billion acquisition of Kite Pharma Inc., a maker of cancer drugs, and its recent research and development collaboration with Belgium-based Galapagos NV, a company focusing on inflammation and immunology treatments.

Mr. Dickinson "transformed the way that the company approaches corporate development, expanding the kinds of transactions executed and implementing a broader and more strategic approach to deal-making," Gilead said in a statement.

Analysts expect Gilead to pursue more deals once Mr. Dickinson has established himself as CFO. "They are putting together a team of people who would be very capable of doing that," said Alethia Young, head of health-care research at Cantor Fitzgerald, a financial services firm. "They are messaging that by putting this type of CFO in place."

Gilead declined to comment beyond details included in a press release.

Gilead's balance sheet -- with $30.2 billion in cash, cash equivalents and marketable debt securities at the end of June -- provides Mr. Dickinson with ample flexibility, analysts said.

"They have the balance sheet to do multiple deals with early-stage companies," said Mohit Bansal, a vice president for equity research at Citigroup Inc. Mr. Bansal said he expects the company to spend several billion dollars on transactions similar to the one with Galapagos.

Gilead has various options, including a continued expansion into oncology treatments, cures for hepatitis B or inflammation and immunology drugs, said Salim Syed, head of biotechnology research at Mizuho Americas LLC, a corporate and investment bank. "They have a CFO now that has a history as a mergers-and-acquisitions banker," Mr. Syed said. "Capital allocation becomes a really important question at this point."

Before his time at Gilead, Mr. Dickinson worked for nine years at Lazard Ltd., where he was global co-head of health-care investment banking, and at Myogen Inc., a biopharmaceutical company that was acquired by Gilead in 2006.

Gilead's shares rose 1.2% Tuesday to $65.30.

Write to Nina Trentmann at nina.trentmann@wsj.com

Stocks mentioned in the article
ChangeLast1st jan.
CITIGROUP INC. -1.55% 73.91 Delayed Quote.41.97%
GILEAD SCIENCES -1.54% 63.33 Delayed Quote.1.25%
LAZARD LTD -1.79% 37.76 Delayed Quote.2.30%
ROCHE HOLDING AG -0.07% 297.9 Delayed Quote.22.39%
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GILEAD SCIENCES
11/11GILEAD SCIENCES : New Data on Filgotinib in Rheumatoid Arthritis Demonstrate Dur..
AQ
11/11GILEAD SCIENCES : Data Showing Potential for Machine Learning to Advance Underst..
AQ
11/11GILEAD SCIENCES : Announces New Data from Viral Hepatitis Research Programs at T..
AQ
11/11GILEAD SCIENCES : Presents Data on Investigational HIV-1 Capsid Inhibitor GS-620..
AQ
11/08GILEAD SCIENCES : Did You Invest in Gilead Sciences?
BU
11/08GILEAD SCIENCES : Presents Data on Investigational HIV-1 Capsid Inhibitor GS-620..
BU
11/08GILEAD SCIENCES : Data Showing Potential for Machine Learning to Advance Underst..
BU
11/08GILEAD SCIENCES : Announces New Data from Viral Hepatitis Research Programs at T..
BU
11/07GILEAD SCIENCES : United States sues Gilead for patent violation on HIV preventi..
AQ
11/07Health Care Up After Teva, Cardinal Health Reports -- Health Care Roundup
DJ
More news
Financials (USD)
Sales 2019 22 290 M
EBIT 2019 11 488 M
Net income 2019 4 319 M
Finance 2019 2 986 M
Yield 2019 3,96%
P/E ratio 2019 17,7x
P/E ratio 2020 11,3x
EV / Sales2019 3,46x
EV / Sales2020 3,35x
Capitalization 80 122 M
Chart GILEAD SCIENCES
Duration : Period :
Gilead Sciences Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GILEAD SCIENCES
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 30
Average target price 78,00  $
Last Close Price 63,33  $
Spread / Highest target 50,0%
Spread / Average Target 23,2%
Spread / Lowest Target -5,26%
EPS Revisions
Managers
NameTitle
Daniel O'Day Chairman & Chief Executive Officer
Andrew D. Dickinson Chief Financial Officer
Merdad V. Parsey Chief Medical Officer
George Pratt Shultz Director-Emeritus
Gayle Edlund Wilson Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES1.25%80 122
VERTEX PHARMACEUTICALS24.98%50 394
REGENERON PHARMACEUTICALS-6.75%35 474
WUXI APPTEC CO., LTD.73.14%21 914
GENMAB39.72%14 081
BEIGENE, LTD.40.67%11 493